论文部分内容阅读
目的:分析急性髓系白血病中伴3q异常核型患者的临床特征。方法:对224例急性髓系白血病患者进行G显带核型分析,对存在t(3q)、inv(3q)、add(3q)、del(3q)或ins(3)等的患者回顾性分析其诊断、治疗、预后等因素。结果:共有6例患者经核型分析表明存在3q异常核型,4例为原发性急性髓系白血病,2例为MDS转变而来。患者经予常规化疗方案或加入临床研究方案化疗,1例患者完全缓解后复发,1例患者未完成化疗,其他患者化疗后均未缓解,总中位生存时间为(7.00±5.44)个月,生存期1～14个月。结论:伴3q异常核型的AML患者治疗效果不佳,但不同核型的临床意义尚需进一步的大规模临床研究证实。
Objective: To analyze the clinical features of acute myeloid leukemia patients with 3q abnormal karyotype. Methods: A retrospective analysis of 224 cases of acute myeloid leukemia patients with G-banding karyotype analysis of patients with t (3q), inv (3q), add (3q), del (3q) or ins (3) The diagnosis, treatment, prognosis and other factors. RESULTS: A total of 6 patients showed karyotyping of 3q with karyotyping, 4 with primary acute myeloid leukemia and 2 with MDS. Patients underwent conventional chemotherapy or chemotherapy regimen. One patient relapsed after complete remission, one patient did not complete chemotherapy, and the other patients did not relieve after chemotherapy. The median overall survival time was (7.00 ± 5.44) months, Survival of 1 to 14 months. CONCLUSION: AML patients with 3q abnormal karyotype have poor therapeutic effect, but the clinical significance of different karyotypes still needs further large-scale clinical studies.